Bioasis Technologies Inc. Announces Warrant Extension

MARCH 25, 2019 GUILFORD, CONN., BIOASIS TECHNOLOGIES INC. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has applied for approval from the TSX Venture Exchange to extend the expiry date of 5,797,795 common share purchase warrants issued to subscribers pursuant to the private placement of units which closed on April 11, 2017. Bioasis intends to extend the expiry date of the warrants from April 11, 2019 until April 11, 2021. The exercise price of $1.00 per share and all other terms of the warrants will remain unchanged for the extended exercise period. The extension is subject to approval from the TSX Venture Exchange.

Koo